Badawoud Amal Mohammad, Ali Lashin Saad, Abdallah Mahmoud S, El Sabaa Ramy M, Bahaa Mostafa M, Elmasry Thanaa A, Wahsh Eman, Yasser Mohamed, Eltantawy Nashwa, Eldesoqui Mamdouh, Hamouda Manal A
Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Department of Basic Medical Science, Faculty of Dentistry, Al-Ahliyya Amman University, Amman, Jordan.
Front Pharmacol. 2024 Jul 31;15:1434512. doi: 10.3389/fphar.2024.1434512. eCollection 2024.
Parkinson's disease (PD) is a neurological condition that typically shows up with aging. It is characterized by generalized slowness of movement, resting tremor or stiffness, and bradykinesia. PD patients' brains mostly exhibit an increase in inflammatory mediators and microglial response. Nevertheless, a variety of non-steroidal anti-inflammatory medications (NSAIDS) offered neuroprotection in animal models and preclinical trials. The current systematic review and meta-analysis were designed to try to resolve the debate over the association of NSAID use with the development of PD because the results of several studies were somehow contradictory. An intense search was performed on Scopus, PubMed, and Web of Science databases for articles relating the incidence of PD to the use of NSAIDs. Statistical analysis of the included studies was carried out using Review Manager version 5.4.1 by random effect model. The outcome was identified as the development of PD in patients who were on NSAIDs, ibuprofen only, aspirin only, and non-aspirin NSAIDs. This was analyzed using pooled analysis of odds ratio (OR) at a significance level of ≤0.05 and a confidence level of 95%. A statistically significant decreased risk of PD was observed in patients taking NSAIDs, Ibuprofen, and non-aspirin NSAIDs. The ORs of PD occurrence in patients who took NSAIDs, Ibuprofen, and non-aspirin NSAIDs were 0.88 [95% CI (0.8-0.97), = 0.01], 0.73 [95% CI (0.53-1), = 0.05] and 0.85 [95% CI (0.75-0.97), = 0.01]. Meanwhile, the risk of PD in patients who took aspirin was not statistically significant. In conclusion, Ibuprofen, non-aspirin NSAIDs, and other types of NSAIDs could be associated with a reduction in PD risk. However, there was no association between aspirin intake and the development of PD.
帕金森病（PD）是一种通常随着年龄增长而出现的神经系统疾病。其特征为运动普遍迟缓、静止性震颤或僵硬以及运动迟缓。帕金森病患者的大脑大多表现出炎症介质增加和小胶质细胞反应。然而，多种非甾体抗炎药（NSAIDs）在动物模型和临床试验中具有神经保护作用。当前的系统评价和荟萃分析旨在试图解决关于使用NSAIDs与帕金森病发生之间关联的争议，因为多项研究的结果存在一定矛盾。我们在Scopus、PubMed和科学网数据库中进行了全面检索，以查找与帕金森病发病率和使用NSAIDs相关的文章。使用Review Manager 5.4.1软件通过随机效应模型对纳入研究进行统计分析。结果确定为使用NSAIDs、仅使用布洛芬、仅使用阿司匹林以及使用非阿司匹林类NSAIDs的患者中帕金森病的发生情况。使用比值比（OR）的合并分析在显著性水平≤0.05和置信水平95%下进行分析。在服用NSAIDs、布洛芬和非阿司匹林类NSAIDs的患者中观察到帕金森病风险显著降低。服用NSAIDs、布洛芬和非阿司匹林类NSAIDs的患者发生帕金森病的OR分别为0.88 [95%可信区间（CI）（0.8 - 0.97），P = 0.01]、0.73 [95% CI（0.53 - 1），P = 0.05]和0.85 [95% CI（0.75 - 0.97），P = 0.01]。同时，服用阿司匹林的患者患帕金森病的风险无统计学意义。总之，布洛芬、非阿司匹林类NSAIDs以及其他类型的NSAIDs可能与帕金森病风险降低有关。然而，阿司匹林摄入与帕金森病的发生之间没有关联。
